MicrobioSeq introduces a de novo whole fungal genome sequencing platform to facilitate microbial research

0

To help scientific researchers better understand fungal biodiversity, physiology, metabolism and function, CD Genomics MicrobioSeq has launched the de novo whole fungal genome sequencing service.

New York, USA – April 25, 2022 – MicrobioSeq represents the microbial genomics division of CD Genomics, headquartered in New York, USA. CD Genomics is a genomics services company with a solid reputation for providing reliable sequencing, genotyping, microarray and bioinformatics services. To help scientific researchers better understand fungal biodiversity, physiology, metabolism and function, CD Genomics MicrobioSeq has launched the de novo whole fungal genome sequencing service.

Mushrooms are vital to the biosphere and human health due to their important medicinal and economic value. Some fungi are closely related to animals, plants, and other life forms by forming symbiotic relationships. Fungi also produce some secondary metabolites such as penicillin, cyclosporine, and lovastatin that have important medicinal, agricultural, or cosmetic benefits.

Fungal genome research is a method to obtain the entire fungal genome sequence through genome sequencing and assembly and study its structure and function. Thorough research into these strains also allows us to better understand and utilize mushroom resources to create greater value.

Conventional techniques cannot handle the large amount of data required for fungal genome-wide research because fungal genomes are typically large and complex. At present, the strategy of combined assembly of short-read and long-read sequencing can realize the advanced assembly of mushrooms, and some projects can be assembled at the level near the finished map, which is a strong support for mushroom research.

“CD Genomics uses both long-read and short-read sequencing technologies for de novo sequencing of the whole fungal genome. Both the PacBio and Nanopore platforms are superior long-read sequencing platforms that generate reads tens of kilobases in length for better genome reconstruction. A single molecule of DNA can be sequenced without the need for PCR amplification or chemical labeling of the sample. De novo assembly from long reads can span the regions of low complexity and repetition and create accurate assemblies. Additionally, we perform de novo whole fungal genome sequencing on Illumina HiSeq, a high-fidelity, short-read sequencing platform,” said Dianna, CD Genomics Marketing Manager.

“Whole fungal genome de novo sequencing used to study new fungal populations enables fungal genome reconstruction, functional analysis and evolutionary studies. This technique can shed light on the biodiversity of fungi and yeast, thus expanding research in agronomy, ecology, bioremediation, medicine, cosmetics, bioenergy and biotechnology,” she added.

Benefits of CD Genomics de novo whole fungal genome sequencing:

1. The lowest level of bias and longer read lengths (average > 15,000 bp, some reads > 100,000 bp) produced by long-read sequencing instruments.

2. Advanced Sequencing Platforms: Illumina HiSeq, Nanopore MinION, and PacBio Sequel platforms.

3. Extensive experience in the genomic services industry.

4. Professional bioinformatics analysis team.

Through the MicrobioSeq Division of CD Genomics

MicrobioSeq is the microbial genomics division of CD Genomics, a genomics services company with a reputation for providing reliable microbial sampling products, microbial testing services, microbial genomics services and integrated bioinformatics services.

media contact
Name of the company: CD genomics
Interlocutor: Kiko Garcia
E-mail: Send e-mail
Phone: 1-631-259-7705
Country: United States
Website: https://www.cd-genomics.com

Share.

Comments are closed.